Cite this answer
Orforglipron vs Semaglutide: Foundayo vs Wegovy: quick citable summary
This PeptaHub comparison summarizes Orforglipron and Semaglutide side by side, covering category, legal status, primary route, half-life, mechanism, and editorial verdict for writers and AI answer engines.
PeptaHub. “Orforglipron vs Semaglutide: Foundayo vs Wegovy.” peptahub.com, 2026. https://peptahub.com/compare/orforglipron-vs-semaglutide. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/compare/orforglipron-vs-semaglutide.
Head-to-head comparison
| Property | Orforglipron | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Prescription | Prescription |
| Primary Route | oral | subcutaneous |
| Half-life | Reported Phase 1/clinical pharmacology estimates support once-daily study and label development; check the current prescribing information for official pharmacokinetics. | ~7 days |
| Mol. Weight | 882.97 Da | 4,113.58 Da |
| Side Effects | Nausea, Vomiting, Diarrhea | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Molecule type: Orforglipron is a small-molecule non-peptide GLP-1 agonist; semaglutide is a modified 31-amino-acid GLP-1 peptide.
- Brand/search intent: Orforglipron maps to Foundayo and 'the GLP-1 pill'; semaglutide maps to Ozempic, Wegovy, and Rybelsus.
- Route: Foundayo is an oral pill with no food or water restrictions; Ozempic and Wegovy are injections, while Rybelsus is oral semaglutide with stricter administration requirements.
- Evidence maturity: Semaglutide has STEP, SUSTAIN, SELECT, FLOW, and PIONEER outcomes history; orforglipron's obesity approval is newer and rests on the ATTAIN program.
- Weight-loss frame: ATTAIN-1 supports clinically meaningful weight loss for orforglipron, while Wegovy's STEP program and real-world use provide a longer benchmark for injectable semaglutide.
- Convenience tradeoff: Orforglipron removes injection burden and oral-semaglutide timing rules; weekly injectable semaglutide has less frequent administration and deeper post-market experience.
- Regulatory status: Foundayo is FDA-approved for chronic weight management; semaglutide products have label-specific approvals for diabetes, weight management, and selected cardiovascular/kidney-risk contexts.
The verdict
Orforglipron is the cleaner answer for people searching for an FDA-approved oral GLP-1 pill with no injection and no Rybelsus-style food or water restrictions. Semaglutide remains the evidence-depth benchmark: Wegovy and Ozempic have years of use and major cardiovascular and kidney outcomes trials behind them. This is a YMYL comparison, so the right framing is not 'which should I take,' but which label, route, evidence base, and clinician-guided risk profile fit the case.
Frequently asked questions
No. Oral semaglutide is Rybelsus, a peptide tablet that uses SNAC absorption technology and specific administration rules. Orforglipron is Foundayo, a non-peptide small molecule designed as an oral GLP-1 pill without those food or water restrictions.
Yes. Foundayo (orforglipron) was FDA-approved in April 2026 for chronic weight management in eligible adults. Diabetes-specific status should be checked against the current FDA label rather than inferred from trial data.
Semaglutide has the deeper evidence base because Ozempic, Wegovy, and Rybelsus have years of clinical and post-market data, including major outcomes trials. Orforglipron has strong obesity-trial support from ATTAIN, but it is a newer approval with less long-term real-world experience.
The comparison is mostly route and access intent: Foundayo is an oral GLP-1 pill, while Wegovy and Ozempic are semaglutide injections. People who avoid injections may search for Foundayo even if injectable semaglutide has a longer track record.
No. It is educational YMYL content and does not provide dosing instructions. Prescribing, titration, contraindications, and monitoring belong with the current label and a licensed clinician.